Amrutanjan Health Care Limited (AMRUTANJAN) AI Stock Analysis

• Market Cap: ₹15.01B
• Dividend Yield: 0.68%
• Average Volume (3M): 587.00
• Price to Earnings (P/E): 24.8
• Beta (1Y): 0.96
• Revenue Growth: 7.36%
• EPS Growth: 19.31%
• Country: IN
• Employees: 634
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 6.73
• Shares Outstanding: 29,230,630
• 10 Day Avg. Volume: 607
• 30 Day Avg. Volume: 587
• PEG Ratio: 2.73
• Price to Book (P/B): 5.70
• Price to Sales (P/S): 4.13
• P/FCF Ratio: 121.26
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 72 Outperform
• Price Target: ₹570.00 ▼(-15.12% Downside)
• Action: Upgraded Date: 10/18/25
• Date: Action: Upgraded 10/18/25

Amrutanjan Health Care Limited scores well due to its strong financial performance, characterized by consistent revenue and profit growth, and a solid balance sheet. The technical analysis suggests a neutral to slightly bearish outlook, while the valuation indicates the stock is fairly priced. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Strong balance sheet / low leverage

Low debt-to-equity and growing shareholders' equity provide durable financial flexibility. Substantial cash reserves support liquidity, reduce refinancing risk, and allow the company to invest in distribution, marketing, or M&A without stressing operations over the next several months.

Consistent revenue and profit growth

Multi-year revenue and profit growth with healthy gross and net margins indicate resilient demand for core OTC products and effective pricing. This trend supports predictable cash generation and the ability to sustain marketing and distribution investments over time.

Healthy operating cash flow conversion

Consistent operating cash flow and efficient capex management show the business converts earnings into cash reliably. This underpins working capital needs, funds routine investments and supports shareholder returns or strategic actions without relying on external financing.

Negative Factors

Margin variability / cost control issues

Variability in operating margins signals persistent cost-pressure risks (raw materials, distribution or SG&A). If structural cost control is not improved, margin volatility could erode profitability and cash flow resilience, constraining long-term investment and returns.

Inconsistent free cash flow growth

Irregular FCF growth reduces predictability of funds available for dividends, buybacks or expansion. This volatility can limit strategic flexibility and increase reliance on working capital management or external funding during weaker cash periods.

Modest dividend income

A low dividend yield indicates limited direct cash returns to shareholders and may signal conservative payout policy. For income-focused investors this reduces appeal; retained earnings must clearly translate into growth or higher future payouts to justify the trade-off.

Amrutanjan Health Care Limited Business Overview & Revenue Model

Company Description

Amrutanjan Health Care Limited manufactures, supplies, and sells ayurvedic pain balms, non-alcoholic beverages, and sanitary napkins. The company operates through OTC Products, Beverages, and Others segments. It provides pain management products comprising pain balms and roll-ons; and back pain roll-ons and lotions, body pain gels, and joint muscle sprays, as well as diclofenac, a non-steroidal anti-inflammatory drug. The company offers congestion management products that consists of cold rubs, cough syrups, nasal inhalers, and swas mints. It also provides sanitary napkins for women. In addition, the company offers corn caps; hand sanitizers; and juice drinks under the Fruitnik and Fruitnik Electro+ brand names, as well as operates a pain management center. It exports its products to the Middle East, Africa, South East Asia, and internationally. The company was formerly known as Amrutanjan Limited and changed its name to Amrutanjan Health Care Limited in 2007. Amrutanjan Health Care Limited was founded in 1893 and is based in Chennai, India.

How the Company Makes Money

Amrutanjan Health Care Limited primarily makes money by manufacturing and selling branded OTC consumer healthcare products. Its core revenue stream comes from sales of pain-management products (notably topical analgesic balms and related pain-relief formats) marketed under the Amrutanjan brand, where earnings are driven by consumer demand, brand recognition, pricing, and repeat purchase behavior typical of OTC categories. The company generates revenue through distribution-led sales into retail and pharmacy channels as well as other trade channels used for FMCG/OTC products; revenue is recognized from the sale of finished goods to channel partners/customers. Profitability is influenced by product mix (higher-margin branded products vs. other offerings), input and packaging costs, advertising and promotion spend to sustain brand awareness, and the breadth/efficiency of its distribution network. Specific details on major partnerships, customer concentration, or segment-wise revenue breakdown are null.

Amrutanjan Health Care Limited Financial Statement Overview

Summary

Amrutanjan Health Care Limited demonstrates strong financial health with consistent revenue and profit growth, solid balance sheet management, and healthy cash flows. While the company shows strong profitability and liquidity, the variability in certain operational metrics indicates areas for improvement in efficiency and cost control.

Income Statement

Amrutanjan Health Care Limited shows a solid performance with steady revenue growth, increasing from 2020 to 2025. Gross and net profit margins are healthy, indicating strong profitability. However, fluctuations in EBIT and EBITDA margins over the years suggest some cost management challenges.

Balance Sheet

The company maintains a strong balance sheet with a low debt-to-equity ratio, indicating prudent leverage management. Consistent growth in stockholders' equity and a robust equity ratio underpin financial stability. The cash reserves are substantial, enhancing liquidity.

Cash Flow

Cash flow analysis reveals a positive trend in operating cash flow and effective capital expenditure management. However, free cash flow growth has been inconsistent, suggesting potential volatility in cash generation. The company maintains a healthy operating cash flow to net income ratio, indicating efficient cash conversion.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	4.70B	4.51B	4.21B	3.80B	4.05B	3.32B
Gross Profit	2.43B	2.46B	1.46B	1.98B	2.25B	1.91B
EBITDA	839.37M	758.79M	681.60M	590.79M	946.99M	861.66M
Net Income	566.96M	508.35M	449.73M	398.35M	671.89M	611.90M
Balance Sheet
Total Assets	4.32B	4.21B	3.67B	3.62B	3.50B	2.74B
Cash, Cash Equivalents and Short-Term Investments	2.07B	1.95B	2.07B	1.93B	2.01B	1.75B
Total Debt	19.32M	20.78M	17.28M	9.09M	8.80M	13.42M
Total Liabilities	902.90M	947.73M	783.82M	713.21M	847.44M	587.06M
Stockholders Equity	3.42B	3.27B	2.88B	2.91B	2.65B	2.16B
Cash Flow
Free Cash Flow	-78.22M	153.46M	211.93M	102.91M	287.32M	878.02M
Operating Cash Flow	109.07M	508.99M	279.11M	192.18M	521.96M	897.63M
Investing Cash Flow	-82.16M	-309.66M	191.65M	-24.75M	-362.12M	-877.61M
Financing Cash Flow	-76.94M	-134.90M	-482.66M	-140.26M	-167.02M	-62.83M

Amrutanjan Health Care Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 671.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:AMRUTANJAN, the sentiment is Negative. The current price of 671.5 is above the 20-day moving average (MA) of 562.90, above the 50-day MA of 593.66, and below the 200-day MA of 675.20, indicating a bearish trend. The MACD of -25.67 indicates Positive momentum. The RSI at 22.22 is Positive, neither overbought nor oversold. The STOCH value of 8.02 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:AMRUTANJAN.

Amrutanjan Health Care Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMRUTANJAN	72 Outperform	₹15.01B	24.83	―	0.68%	7.36%	19.31%
TTKHLTCARE	64 Neutral	₹11.48B	34.84	―	0.95%	6.98%	-17.11%
KRSNAA	62 Neutral	₹19.01B	38.37	―	0.38%	11.51%	21.56%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INDOCO	49 Neutral	₹17.66B	-18.14	―	0.08%	-2.81%	-444.69%
ZOTA	41 Neutral	₹33.29B	-40.91	―	0.06%	82.58%	-63.05%